ACTU

Actuate Therapeutics Inc

Add to Watchlist

Advanced Chart

6.990

+0.39(5.909%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

7.100

Open

6.600

VWAP

6.84

Vol

123.46K

Mkt Cap

137.14M

Low

6.4516

Amount

844.76K

EV/EBITDA(TTM)

Total Shares

19.62M

126.01M

EV/OCF(TTM)

P/S(TTM)

Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). The Company is developing elraglusib, a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3b, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, which lead to tumor cell survival, growth, migration, and invasion. Its candidate products are Elraglusib Injection and Elraglusib Oral Tablet. Elraglusib is the lead drug in the portfolio and is being evaluated in a randomized Phase II trial in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). Elraglusib is designed to act as a mediator of antitumor immunity through the inhibition of NF-kB and regulates multiple immune checkpoints and immune cell function.

2 Analyst Rating

271.96% Upside

Wall Street analysts forecast ACTU stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ACTU is 26.00 USD with a low forecast of 20.00 USD and a high forecast of 32.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

0 Hold

0 Sell

Moderate Buy

271.96% Upside

Current: 6.990

Low

20.00

Averages

26.00

High

32.00

271.96% Upside

Current: 6.990

Low

20.00

Averages

26.00

High

32.00

HC Wainwright & Co.

Swayampakula Ramakanth

Strong Buy

Initiates

$20

2025-03-17

Reason

HC Wainwright & Co.

Swayampakula Ramakanth

Price Target

$20

2025-03-17

Initiates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Actuate Therapeutics Inc (ACTU.O) is 0.00, compared to its 5-year average forward P/E of -0.06. For a more detailed relative valuation and DCF analysis to assess Actuate Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-0.06

Current PE

0.00

Overvalued PE

0.50

Undervalued PE

-0.63

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00

Financials

Annual

Quarterly

FY2025Q1

YoY :

-18.11%

-6.37M

Operating Profit

FY2025Q1

YoY :

-23.86%

-6.32M

Net Income after Tax

FY2025Q1

YoY :

-25.58%

-0.32

EPS - Diluted

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

825.0K

USD

Bought

0-3

1.5M

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

12.0M

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

0.0

Volume

Months

6-9

55.3K

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

825.0K

USD

Bought

0-3

1.5M

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

12.0M

USD

Months

ACTU News & Events

Events Timeline

2025-07-17 (ET)

2025-07-17

08:50:59

Actuate Therapeutics announces end of Phase 1 portion of elraglusib study

2025-06-24 (ET)

2025-06-24

09:20:48

Actuate highlights results from subgroup analysis of Phase 2 elraglusib trial

2025-06-20 (ET)

2025-06-20

08:46:48

Actuate reports biomarker, machine learning data from Phase 2 elraglusib trial

News

3.0

07-11NASDAQ.COM

RSSL's Underlying Holdings Imply 20% Gain Potential

9.0

06-24NASDAQ.COM

Actuate's Elraglusib Shows Strong Survival Benefit In Metastatic Pancreatic Cancer

9.0

06-24Newsfilter

Actuate Therapeutics Highlights Significant and Sustained Survival Benefit in Key Metastatic Pancreatic Cancer Patient Populations in Phase 2 Elraglusib Trial